Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis

Arthritis and Rheumatism

Volumn 63, Issue 3, 2011, Pages 670-680

  Polzer, Karin ^a   Neubert, Kirsten ^a   Meister, Silke ^a   Frey, Benjamin ^a   Baum, Wolfgang ^a   Distler, Jörg H ^a   Gückel, Eva ^a   Schett, Georg ^a   Voll, Reinhard E ^a   Zwerina, Jochen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; NUCLEAR FACTOR OF ACTIVATED T CELL C1; PHOSPHATE BUFFERED SALINE; PROTEASOME INHIBITOR; PROTEIN C FOS; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; BONE DISEASE; BONE EROSION; BONE MARROW; BONE TURNOVER; CARTILAGE INJURY; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HETEROZYGOSITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SYNOVITIS; SYNOVIUM; TRANSGENIC ANIMAL; TREATMENT DURATION; UBIQUITINATION; WILD TYPE;

ANIMALS; ARTHRITIS; BONE AND BONES; BONE RESORPTION; BORONIC ACIDS; CARTILAGE, ARTICULAR; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOPROTEGERIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; RANK LIGAND; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953705982     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30177     Document Type: Article

References (17)

1. Firestein GS. Evolving concepts of rheumatoid arthritis [review]. Nature 2003;423:356-61. (Pubitemid 40852711)
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
3. Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008;14:245-53.
4. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1:47-54.
5. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54: 3761-73. (Pubitemid 44955876)
6. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342-9. (Pubitemid 46189798)
7. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008;8:1053-72.
8. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67:1783-92. (Pubitemid 46383406)
9. Von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34. (Pubitemid 47299978)
10. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling. Blood 2009;113: 4319-30.
11. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumornecrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50: 277-90. (Pubitemid 38084313)
12. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72. (Pubitemid 43228620)
13. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55. (Pubitemid 351951516)
14. Hayer S, Polzer K, Brandl A, Zwerina J, Kireva T, Smolen JS, et al. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res 2008;23:1650-60.
15. Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008;32:1661-8.
16. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al. Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40. (Pubitemid 36418398)
17. Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009;68: 1761-7.